Key Updates on Brentuximab Vedotin for Classical Hodgkin Lymphoma
At the 2019 American Society of Hematology (ASH) Annual Meeting, Andrew Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey, New Brunswick, moderated a panel discussion highlighting key updates on the use of brentuximab vedotin for the treatment of patients with classical Hodgkin lymphoma.
The panel included Julie Vose, MD, MBA, University of Nebraska Medical Center, Omaha; Jonathan Friedberg, MD, MMSc, University of Rochester Medical Center, New York; and Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, Minnesota.
Watch the 6-part video series below!
---
ECHELON-1 Approach in Classical Hodgkin Lymphoma
In the first installment of this panel discussion series, Dr Evens, Dr Vose, Dr Friedberg, and Dr Ansell discuss results from the ECHELON-1 study and how these results have impacted the treatment of patients with high-risk classical Hodgkin lymphoma.
Brentuximab Vedotin Plus AVD Promising in HIV-Associated Classical Hodgkin Lymphoma
In the second installment of this panel discussion series, Dr Evens, Dr Vose, Dr Friedberg, and Dr Ansell discuss safety and efficacy results from a phase 2 study looking at brentuximab vedotin in combination with AVD for patients with HIV-associated classical Hodgkin lymphoma.
In the third installment of this panel discussion series, Dr Evens, Dr Vose, Dr Friedberg, and Dr Ansell discuss results from a phase 2 study assessing frontline brentuximab vedotin plus nivolumab in older patients with Hodgkin lymphoma.
Brentuximab Vedotin Plus Rituximab Safe, Effective for PTLD
In the fourth installment of this panel discussion series, Dr Evens, Dr Vose, Dr Friedberg, and Dr Ansell discuss results from a phase 1/2 trial exploring the combination of brentuximab vedotin plus rituximab in patients with immunosuppression-associated and/or EBV-positive lymphomas.
Incorporating Novel Agents in the Treatment Landscape of Hodgkin Lymphoma
In the fifth installment of this panel discussion series, Dr Evens, Dr Vose, Dr Friedberg, and Dr Ansell discuss how to incorporate novel agents in the treatment of patients with relapsed/refractory classical Hodgkin lymphoma and some of the challenges to doing so.
Brentuximab Vedotin Plus Nivolumab Well-Tolerated Long-Term for Relapsed/Refractory Hodgkin Lymphoma
In the final installment of this panel discussion series, Dr Evens, Dr Vose, Dr Friedberg, and Dr Ansell discuss long-term results from a phase 1/2 single-arm study of brentuximab vedotin plus nivolumab in relapsed/refractory classical Hodgkin lymphoma and the role of allogeneic transplantation in the treatment of this disease.
